Snapshot from May 31, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Ionis Pharmaceuticals
Company

Ionis Pharmaceuticals

Tracked across 1 events · 7 articles · First seen May 14, 2026 · Last active May 14, 2026

Sentiment
50
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 50
Tech
Biogen Diranersen Phase 2 Alzheimer's Results
Biogen announced compelling topline results from its Phase 2 CELIA study for diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau in individuals with early Alzheimer's disease. The study demonstrated robust reductions in tau…
Impact: Ionis Pharmaceuticals discovered diranersen and licensed it to Biogen in 2019, making it a beneficiary of any future success of the drug.
May 14, 2026 · 7 articles
Key Actions (1)
30 Biogen exercised license option Ionis PharmaceuticalsBiogen Diranersen Phase 2...
NEWSDESK
Track Ionis Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.